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Abstract
Background: Anti-malarial drug resistance has emerged as one of the biggest challenges confronting the
worldwide effort to control malaria. The appearance of chloroquine and multi-drug resistance had devastating
effects on therapeutic efficacy of former first-line agents. Artemisinin has proven to be an excellent therapeutic
alternative to fill the void in chemotherapeutic options left by resistance mechanisms. At the time of introduction,
no resistance to artemisinins had been recorded, and artemisinins demonstrated excellent parasite reduction rates.
In an attempt to protect artemisinin efficacy, the World Health Organization (WHO) made artemisinin-based
combination therapy (ACT) its official first-line treatment recommendation for uncomplicated Plasmodium
falciparum in 2006. In Brazil, artemether/lumefantrine became the Brazilian Malaria Control Programme’s official
treatment recommendation in 2007. The sarco/endoplasmic reticulum Ca
2+ - ATPase ortholog of P. falciparum
(pfatp6) has been suggested as one of the targets of artemisinins. Consequently, pfatp6 gene polymorphisms are
being investigated as markers of artemisinin resistance elsewhere. The goal of this work was to describe the
molecular profile of pfatp6i nP. falciparum isolates from different localities in the Amazonas State.
Methods: DNA polymorphisms of the pfatp6 gene in 80 P. falciparum isolates from 11 municipalities of the
Amazonas State (Western Brazilian Amazon), before and after the introduction of ACT in the Brazilian anti-malarial
guidelines, were analysed by automatic sequencing. Mutations in the pfatp6 gene were searched using Mutation
Surveyor v3.25 software.
Results: The P. falciparum pfatp6 gene presented polymorphisms at codons 37, 630 and 898. The R37K mutation
was found in 16% of the samples, A630S in 32% and I898I in 52%. No S769N mutation, however, was detected in
the analysed samples.
Conclusion: Despite the small number of samples, data presented here provide baseline information about
polymorphisms of pfatp6 gene before and after exposure to ACT in a low transmission area, which will help to
infer drug selection pressure in this area in the future.
Keywords: Malaria, Plasmodium falciparum, Artemisinin, Molecular marker, pfatp6, Polymorphisms, Amazon
Background
The Brazilian Amazon Region is responsible for 99.8%
of all reported malarial cases in the Brazil, where socioe-
conomic and environmental conditions favor the prolif-
eration of the Anopheles darlingi mosquito. In the State
of Amazonas, where this study was conducted, 32,566
cases were reported from January to July in 2010,
making it the second most malaria-affected state in Bra-
zil after Pará (51,697 cases). Plasmodium vivax accounts
for 83.7% of these, but Plasmodium falciparum accounts
for the majority of the remaining cases [1].
Plasmodium falciparum resistance to anti-malarial
drugs, especially chloroquine and pyrimethamine-sul-
phadoxine, has emerged as one of the biggest challenges
to be faced in malaria control [2]. Artemisinin-based
combination therapy (ACT) is now the WHO recom-
mended strategy for preventing the development of drug
resistance, and, in Brazil, artemether-lumefantrine was
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Health’s first-line treatment recommendation for
uncomplicated falciparum infections. The efficacy of
this strategy, however, has become threatened by the
discovery of delayed artemisinin sensitivity on the Thai-
Cambodian border [3]. The identification and monitor-
ing of indicators of artemisinin resistance is essential for
preservation of ACT efficacy [4]. Two genes, originally
shown to modulate sensitivity to chloroquine in P. falci-
parum, have been investigated in the context of artemi-
sinin resistance: pfmdr1 and pfcrt, but failed to correlate
with the clinical phenotype of delayed parasite clearance.
A previous study, however, with P. falciparum suggested
that a sarcoplasmic and endoplasmic reticulum Ca
2
+-ATPase (SERCA)-type protein encoded by the gene
pfatp6 m i g h tb et h ep r i m a r yt a r g e to ft h e s ed r u g s[ 5 ]
(Figure 1), and mutations in this gene may alter P. falci-
parum’s sensitivity to artemisinin.
Jambou et al. reported a significant decrease in in vitro
sensitivity to artemether in P. falciparum isolates from
French Guiana, located along Brazil’sn o r t h e r nb o r d e r
[6]. This reduced efficacy was associated with a S769N
polymorphism in the PfATPase6 protein. Although the
significance of this mutation has not been determined,
these observations could indicate that the S769N muta-
tion could be a marker of drug resistance. French Guya-
na’s proximity to Brazil makes migration of drug
resistant parasite populations highly possible [7].
Other polymorphisms have been identified in the
pfatp6 gene: the double mutation E431K, A623E in
Senegal, I89T in Thailand [8], H243Y in Central Africa
[9] and T2694 in São Tomé and Principe [10]. In 2008,
Dahlstrom et al. [11], studying P. falciparum isolates
from East and West Africa, identified 33 single nucleo-
tide polymorphisms (SNPs), three of which were found
in a frequency higher than 5% in codons H431K, N569K
and A630S.
Data on the pfatp6 gene in Brazilian isolates is scarce.
Recently, three mutations were described in samples
from the State of Pará, in nucleotide positions 110, 1916
and 2694 [7]. This study reports pfatp6 gene poly-
morphisms in P. falciparum isolates collected before
and after the introduction of ACT in eleven endemic
municipalities.
Methods
Study design
This is an ecological study aimed at evaluating changes
in the molecular profile of P. falciparum between two
distinct time points: before and after the introduction of
ACT in Brazil.
Samples
Plasmodium falciparum field isolates collected between
2000 and 2005 (60 samples; 10 per year) were obtained
from the FMT-HVD Laboratory of Malaria. Samples
from between 2009 and 2010 (20 samples; 10 per year)
were prospectively collected. Samples from both time
points come from the same eleven endemic municipali-
ties of the Amazonas State (Figure 2). Samples were col-
lected as follows: two from Autazes, one from Barcelos,
one from Borba, three from Careiro, three from Coari,
two from Guajará, two from Humaitá, six from Itacoa-
tiara, 53 samples from Manaus, one from São Gabriel
da Cachoeira and six from Tefé. Isolates were collected
from patients with uncomplicated P. falciparum infec-
tions before unsupervised anti-malarial treatment (qui-
nine/doxycycline from 2000 to 2005 and artemether/
lumefantrine from 2009 to 2010). As a tertiary care and
referral center for infectious diseases in the State of
Amazonas, the Fundação de Medicina Tropical Dr. Hei-
tor Vieira Dourado (FMT-HVD) routinely follows all
patients diagnosed with malaria for 42 days since the
middle 1990s. Patients come to the outpatient clinics on
days 0, 3, 7, 14, 28 and 42 for clinical evaluation and
thick blood smear collection, as part of a protocol to
characterize anti-malarial resistance. Diagnosis was car-
ried out by microscopic examination of Giemsa-stained
thick blood films as recommended by the Brazilian
Malaria Control Programme. After confirming P. falci-
parum mono-infection, 5 mL of venous blood were col-
lected into an EDTA-containing tube. The tube was
centrifuged to separate plasma, and erythrocytes were
stored at -20°C until DNA extraction.
DNA extraction
Extraction of DNA from patient blood samples infected
with P. falciparum was carried out using a Genomic
DNA Purification kit (Wizard
®, USA) according to the
manufacturer’s protocol.
Figure 1 Pfatpase6–Membrane protein topology and
aminoacid substitutions, evidencing the 769 polymorphism
found in samples from the French Guyana (in the Eastern
Amazon).
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Five pairs of oligonucleotide primers (Table 1) were
designed for amplification of five genomic sequences
between nucleotides 28 to 3078 of the pfatp6 gene. The
fragments were amplified by PCR and the quality of
PCR products generated for each fragment was deter-
mined by 1% agarose gel electrophoresis and visualized
by staining with ethidium bromide. The DNA concen-
tration was measured by NanoDrop
® 2000 (Thermo
Scientific). The template for DNA sequencing following
purification was carried with a commercial kit (SV Gel
and PCR Clean-Up System, Wizard
®, USA).
Sequencing reactions were carried out using an ABI
3130xl genetic analyzer (Applied Biosystems
®,U S A )a s
specified by manufacturer’sp r o t o c o l .D N As e q u e n c e s
were generated from both sense and antisense primers,
aligned to check for genetic polymorphism and com-
pared to the reference sequence of clone 3D7 (accession
PFA0310c in http://www.plasmodb.org). PCR primers
and reaction conditions have been published elsewhere
[10].
Data analysis
Sequence quality was assessed using FinchTV
® v.1.4.0
(Geospiza
®) software. Analysis of polymorphisms was
performed in Mutation Surveyor
® v.3.97 (SoftGenetics
®,
LLC).
Ethical approval
This study, which used retrospective samples (2000-
2005) and prospectively collected samples (2009-2010),
received ethical approval from the Ethics Committee
Board of the FMT-HVD (protocol 3080-08).
Results
Samples from 80 patients with acute P. falciparum
malaria ranging from 13 to 80 years old (71% of which
were males) were studied. No instances of treatment
failure or recrudescence were observed in the 42-day
follow-up period.
PCR amplification and sequencing of P. falciparum
genomic DNA was successful in all isolates included in
this study. A total of three polymorphisms in the pfatp6
gene were identified: two non-synonymous (R37K and
A630S) and one synonymous (I898I). The mutation at
codon 37 lead to the amino acid change Arginine ®
Lysine. While the second mutation at codon 630 lead to
the amino acid change Alanine ® Serine. The third
mutation at codon 898, however, did not lead to any
amino acid change. The prevalence of each mutation
was: 16% for R37K, 32% for A630S and 52% for I898I
(Figure 3). The G2306A mutation (encoding S769N)
was absent in all the samples.
Figure 2 Map of the Amazonas State showing the municipalities where samples originated (1. São Gabriel da Cachoeira; 2. Barcelos;
3. Manaus; 4. Itacoatiara; 5. Careiro; 6. Coari; 7. Tefé; 8. Humaitá; 9. Guajará; 10. Autazes; 11. Borba).
Table 1 Oligonucleotide primers used for PCR
amplification and DNA sequencing of pfatp6 gene
Primer
pair
Sequence 5’®3’ Target region
(bps)
Base
pairs
1F (sense) CATACGATGTTGAGGATGTAC 28-722 694
2R
(antisense)
GACCTATTTCAGTCTTCATACC
3F (sense) GAGAATCCTGTTCAGTTGAC 558-1308 750
4R
(antisense)
ATCCTTCTTCTCCATCATCC
5F (sense) ACCGTGTTTCATTTGTTTAGAG 1138-1892 770
6R
(antisense)
CCATTTGTTGTTGCCTGAGC
7F (sense) AATCACCAAGGGGTATCAAC 1771-2467 711
8R
(antisense)
ACGTATACCAGCCATATGG
9F (sense) TTCAAAATATGGGAAAAAGAGCA 2285-3078 805
10R
(antisense)
TGTTGCTGGTAATCCGTCAG
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The genetic basis of resistance to anti-malarial drugs
can be investigated in several ways. This study describes
for the first time a pfatp6 gene sequence polymorphism
in Amazonas State’s samples in two distinct periods:
before and after the introduction of artemisinins. No
clear change in polymorphism distribution, however,
was observed between the two periods. The major lim-
itation of this study was the small number of samples
due to the declining number of P. falciparum infections.
This decline has been particularly pronounced since the
introduction of ACTs as first-line treatment in 2007.
A study of the susceptibility to artemisinins and deri-
vatives and molecular analysis of SNPs in Africa, found
a silent mutation T2694A in isolates of São Tomé and
Príncipe [10]. In this present study, 40 samples from dif-
ferent municipalities presented this mutation, and were
similarly found to be phenotypically insignificant.
In 2008, Ferreira et al. also published a similar paper
with Brazilian samples [7]. They described the analysis
of four SNPs in isolates from Pará in nucleotide posi-
tions: 110, 1916, 2306 and 2694. In the present study,
no mutations were detected in nucleotides 1916 and
2306. The mutations in nucleotides 110 and 2694, how-
ever, were observed with frequencies of 16% and 52%
respectively.
Polymorphisms similar to the third observed mutation
at nucleotide 1888 in codon 630 in 32% of isolates, were
detected in Nigerian samples (A630S), with a frequency
of 1.1% [12]. The association between the mutation
occurrence and external factors (environment and
human host) was tested by bivariate analysis and showed
no correlation.
The G2306A mutation (encoding S769N), found in
the French Guiana (Eastern Amazon) [6] was absent in
the present samples. That is probably explained by the
fact that not much immigration occurs from that region
to the Amazonas State (Western Brazilian Amazon).
Actually the Amazon represents a wide and diverse area
with distinct transmission scenarios and still with
reduced population mobility, which may parallel the low
dissemination of locally originated mutations [13].
Pfmdr1 copy number was not assessed in this study.
Though pfmdr1 copy number is well correlated with
decreased therapeutic efficacy of many drugs and found
in South America, mefloquine-based ACT is not a first-
line agent in Brazil. Therefore, pfmdr1 is less likely to
be under mefloquine pressure, despite the recent obser-
vation that in vitro response to lumefantrine could also
be associated to pfmdr1 mutations [14]. More genes,
however, in larger samples from a representative portion
of the Amazon should be urgently investigated.
Considering the implication of pfatp6 in artemisinin
resistance, the molecular variability of this gene should
be carefully monitored in areas where P. falciparum
poses a public health threat. Losing artemisinin efficacy
Figure 3 Polymorphism frequencies by year in the pfatp6 gene from samples from different municipalities of the Amazonas State (10
samples analysed per year).
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treatment efforts, because there is no equivalent oral
therapeutic. The gravity of these implications warrants
intensive phenotypic and molecular monitoring of field
isolates.
Conclusion
Pfatp6 S769N mutation, a potential molecular marker of
artemisinin resistance, was not present in the few ana-
lysed samples, as well as changes in polymorphism pre-
valence in P. falciparum isolates from Amazonas State
since the introduction of ACT in 2007. These data pro-
vide a baseline level of genetic variation in a potential
candidate gene for artemisinin resistance and will be of
value in future resistance monitoring studies. Identifica-
tion and monitoring of polymorphisms and mutations
that confer drug resistance to P. falciparum is essential
to the success of malaria prevention programmes.
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